FDA Grants Fast Track Designation To Tioga Pharmaceuticals' Asimadoline For The Treatment Of Diarrhea-Predominant ...
Tioga Pharmaceuticals, Inc. announced that its investigational compound asimadoline has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with diarrhea-predominant irritable bowel syndrome (D-IBS). Tioga is conducting a multi-center Phase 3 clinical trial evaluating asimadoline in D-IBS, conducted under a Special Protocol Assessment ...

FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
SILVER SPRING, Md., June 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ...

Biosimilar and Biomarker Approvals to Cut Costs - Research Report on Micromet, Inc. and CEL-SCI Corporation
MACAU--(Marketwire - 06/13/11) - Today, www.EquityMarketsInc.com announced its research report highlighting Micromet, Inc. (NASDAQ: MITI - News ) and CEL-SCI Corporation (AMEX: CVM - News ). Full content and research is available at www.EquityMarketsInc.com/research.php . This sector demonstrates renewed investor interest as new and lucrative ...